Terns Pharmaceuticals, Inc. (TERN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Terns Pharmaceuticals, Inc.'s filing signal turned positive.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oncology medicines, with a lead asset, TERN-701, an oral allosteric BCR-ABL1 inhibitor targeting chronic myeloid leukemia (CML). The company also has legacy metabolic programs, TERN-501 for MASH and TERN-801 for obesity, for which it is seeking strategic partners. Terns aims to deliver high-impact medicines by reimagining known biology, with all its pipeline candidates internally discovered. The company is currently subject to a pending acquisition by Merck Sharp & Dohme LLC, expected to close in the second quarter of 2026. Terns' strategy is to advance TERN-701 into pivotal development, with planned Phase 3 trials in late 2026 or early 2027.

The company has not generated revenue from product sales to date. Potential future revenue drivers include milestone payments and royalties from its collaboration with Hansoh for TERN-701 in greater China, and potential future product sales if its pipeline candidates achieve regulatory approval and commercialization.